唑来膦酸治疗35例原发性骨质疏松症的疗效及观察  

Efficacy of zoledronic acid for the treatment of 35 primary osteoporosis patients

作　　者：甄东[1] 邱冰[1] 

机构地区：[1]贵州省人民医院骨科,贵阳550001

出　　处：《中国骨质疏松杂志》2012年第2期166-168,共3页Chinese Journal of Osteoporosis

摘　　要：目的观察唑来膦酸治疗原发性骨质疏松症的临床疗效及安全性。方法应用唑来膦酸注射液治疗35例57～85岁原发性骨质疏松症患者,分别观察治疗前后患者骨痛的缓解情况、血钙、磷、碱性磷酸酶、骨钙素、尿DPD/Cr变化情况。采用双能X线骨密度仪测定患者治疗前后骨密度。观察患者治疗后不良反应的发生情况。结果全部患者骨痛症状明显改善,总优良率达100%。血钙、磷、碱性磷酸酶、骨钙素无显著变化,尿DPD/Cr较治疗前显著降低(P<0.01)。骨密度较治疗前显著增加(P<0.01),35例患者均无明显不良反应发生。结论唑来膦酸是治疗原发性骨质疏松症的安全有效性药物。Objective To observe the efficacy and safety of zoledronic acid for the treatment of primary osteoporosis.Methods Thirty-five primary osteoporosis patients aged from 57 to 85 years old were treated with 5mg zoledronic acid.The mitigation of pains and the variation of serum calcium,phosphate,alkaline phosphatase,and urine DPD/Cr were observed before and after the treatment.BMD was measured using dual energy X-ray absorptionmetry（DXA）.The incidence of adverse reactions after the treatment was observed.Results Pain was significantly ameliorated in all patients and the total excellent and good rate was 100%.The result of serum calcium,phosphorus,alkaline phosphatase,and BGP showed no significant change.The result of urinary DPD/Cr after the treatment was significantly lower than that before the treatment（P0.01）.BMD was significantly lower than that before the treatment（P0.01）.No obvious adverse reactions happened in all 35 patients.Conclusion Zoledronic acid is an effective and safe drug for the treatment of primary osteoporosis.

关 键 词：唑来膦酸 原发性骨质疏松症 骨密度 

分 类 号：R453[医药卫生—治疗学]